Autologous dendritic cell-tumor fusion vaccine(Dana-Farber Cancer Institute)(Autologous dendritic cell-tumor fusion vaccine(Dana-Farber Cancer Institute))

概要

基本信息

药物类型

治疗性疫苗、树突状细胞疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

皮肤黑色素瘤

原研机构

Dana-Farber Cancer Institute, Inc.

在研机构-

非在研机构

Dana-Farber Cancer Institute, Inc.

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Autologous dendritic cell-tumor fusion vaccine(Dana-Farber Cancer Institute) 相关的临床试验

NCT00085397

/ Unknown status临床2期IIT

A Randomized Phase II Study of Immunization Against Melanoma Comparing Autologous Dendritic Cells Pulsed With gp100 Peptide to Autologous Dendritic Cells Fused With Autologous Tumor Cells

RATIONALE: Vaccines made from a patient's dendritic cells may make the body build an immune response to kill tumor cells. It is not yet known whether combining vaccine therapy with either gp100 antigen or the patient's tumor cells will cause a stronger immune response and kill more tumor cells.
PURPOSE: This randomized phase II trial is studying vaccine therapy and gp100 antigen to see how well they work compared to vaccine therapy and patient's tumor cells in treating patients with stage III or stage IV melanoma.

开始日期2004-03-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

100 项与 Autologous dendritic cell-tumor fusion vaccine(Dana-Farber Cancer Institute) 相关的临床结果

登录后查看更多信息

100 项与 Autologous dendritic cell-tumor fusion vaccine(Dana-Farber Cancer Institute) 相关的转化医学

登录后查看更多信息

100 项与 Autologous dendritic cell-tumor fusion vaccine(Dana-Farber Cancer Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Autologous dendritic cell-tumor fusion vaccine(Dana-Farber Cancer Institute) 相关的药物交易

登录后查看更多信息